233 related articles for article (PubMed ID: 8261412)
1. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
2. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.
Nguyen CH; Fan E; Riou JF; Bissery MC; Vrignaud P; Lavelle F; Bisagni E
Anticancer Drug Des; 1995 Jun; 10(4):277-97. PubMed ID: 7786395
[TBL] [Abstract][Full Text] [Related]
4. Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.
Nguyen CH; Lavelle F; Riou JF; Bissery MC; Huel C; Bisagni E
Anticancer Drug Des; 1992 Jun; 7(3):235-51. PubMed ID: 1319166
[TBL] [Abstract][Full Text] [Related]
5. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy.
Morjani H; Riou JF; Nabiev I; Lavelle F; Manfait M
Cancer Res; 1993 Oct; 53(20):4784-90. PubMed ID: 8402662
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
[TBL] [Abstract][Full Text] [Related]
9. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
10. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
11. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
Riou JF; Helissey P; Grondard L; Giorgi-Renault S
Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, properties and biological evaluation of substituted furo[3,2-e] and pyrano[3,2-e]pyrido[4,3-b]indoles.
Costache E; Nguyen CH; Guilbaud N; Léonce S; Pierré A; Atassi G; Bisagni E
Anticancer Drug Des; 1998 Jun; 13(4):373-86. PubMed ID: 9627674
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Jaxel C; Kohn KW; Wani MC; Wall ME; Pommier Y
Cancer Res; 1989 Mar; 49(6):1465-9. PubMed ID: 2538227
[TBL] [Abstract][Full Text] [Related]
16. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Karki R; Thapa P; Kang MJ; Jeong TC; Nam JM; Kim HL; Na Y; Cho WJ; Kwon Y; Lee ES
Bioorg Med Chem; 2010 May; 18(9):3066-77. PubMed ID: 20392646
[TBL] [Abstract][Full Text] [Related]
18. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
[TBL] [Abstract][Full Text] [Related]
20. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]